ARWR - ARROWHEAD PHARMACEUTICALS, INC.
IEX Last Trade
19.6
0.225 1.148%
Share volume: 4,724
Last Updated: Thu 26 Dec 2024 04:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$19.38
0.23
1.16%
Fundamental analysis
10%
Profitability
0%
Dept financing
15%
Liquidity
75%
Performance
1%
Performance
5 Days
0.93%
1 Month
4.47%
3 Months
1.08%
6 Months
-26.94%
1 Year
-35.32%
2 Year
-48.50%
Key data
Stock price
$19.60
DAY RANGE
$19.12 - $19.48
52 WEEK RANGE
$17.84 - $39.83
52 WEEK CHANGE
-$36.74
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/29/2024
Company detail
CEO: Christopher R. Anzalone
Region: US
Website: arrowheadpharma.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arrowheadpharma.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.
Recent news